Chapter 71 Ethics and Privacy Considerations for Systems Biology Applications in Predictive and Personalized Medicine

Jake Y. Chen Indiana Center for Systems Biology and Personalized Medicine, USA, Indiana University, **Pan Shi** The Pennsylvania State University, USA

> Adam Culbertson Indiana University, USA

Heng Xu The Pennsylvania State University, USA

USA & Purdue University, USA

Eric M. Meslin Indiana University Center for Bioethics, USA & Indiana University, USA

ABSTRACT

Integrative analysis and modeling of the omics data using systems biology have led to growing interests in the development of predictive and personalized medicine. Personalized medicine enables future physicians to prescribe the right drug to the right patient at the right dosage, by helping them link each patient's genotype to their specific disease conditions. This chapter shares technological, ethical, and social perspectives on emerging personalized medicine applications. First, it examines the history and research trends of pharmacogenomics, systems biology, and personalized medicine. Next, it presents bioethical concerns that arise from dealing with the increasing accumulation of biological samples in many biobanking projects today. Lastly, the chapter describes growing concerns over patient privacy when large amount of individuals' genetic data and clinical data are managed electronically and accessible online.

DOI: 10.4018/978-1-4666-3604-0.ch071

INTRODUCTION

Predictive and personalized medicine based on the use of detailed genetic information is being regarded as a major development in modern medicine (Hood, Heath, Phelps, & Lin, 2004). Despite tremendous success in the past 50 years, conventional medicine which is based on observing and treating of patients' critical signs and symptoms at the physiological, organ, or pathobiological levels, has its limitations when treating complex, polygenic, and chronic disorders such as type-II diabetes, cancer, neurodegenerative diseases, and mental disorders. A primary reason is that, while treatment plans have been standardized, an individual's genetic background varies, the result of which is that some treatment work, some do not help at all and some actually harm. To cancer patients, for example, only by trial and error will the right regimen and drug dosage be eventually prescribed correctly, sometimes after long periods of receiving toxicological side effects or non-response. Genomics, pharmacogenomics, functional genomics, proteomics, and metabolomics-the so called "omics" technologies present biology and medicine with a new set of analytic tools to mine more deeply the genetic data contained in many types of biological molecules in biological samples (B. Palsson, 2002). Taken together, the potential for more integrative analysis and mining of the omics data with computer modeling techniques of multi-scale biological structure, or Systems Biology, have led to the creation of modern molecular medicine that is predictive and personalized (Aebersold et al., 2009). Many promising breakthrough drugs and biomarker molecules are being developed to improve targeted therapeutics of drugs, minimize drugs' side effect, and monitor clinical outcome of treatments. Given these development, it can be expected that more personalized "omic-based" medicine will be adopted as a standard clinical practice to improve health care quality and reduce health care cost (Naylor & Chen, 2010).

As we note below, systems biology aims to unify publicly accumulated knowledge of genes, proteins, molecular functional annotations, molecular interactions, and molecular measurements into integrated in silico models. Driven by advances in systems biology, personalized medicine is expected to gain wide-spread support for clinical adoption (Hood et al., 2004). It is expected that there will be concerns associated with the electronic storage, computerized processing, and online sharing of genomics and functional genomic information among biomedical researchers, health care providers, and patients. Ethical concerns about how this information may be misused or abused arise, as privacy concerns emerge about how to enforce patients' rights to protect their genetic information. In this paper, we provide a historical perspective on the emergence of predictive and personalized medicine, its relationship with systems biology, bioethics concerns when developing biobanks, and privacy considerations when dealing with large amount of electronic molecular medicine data.

PERSONALIZED MEDICINE: THE HISTORY

While medicine has always been, to some extent, "personalized" (for example, even ancient codes of medical ethics spoke of the ethical expectations of physicians to consider the well being of individual patients (Daikos, 2007), our current preoccupation with personalized medicine evolved from the new capacity to take "trial-and-error" out of the modern drug development process (Naylor & Chen, 2010). Unlike personalized medicine practiced for thousands of years, in which clinical symptoms derived at the physiological level (e.g., pulse rhythms, tongue color, temperature, pain points, and facial characteristics) were used to "personalize" diagnosis and treatment regimen (e.g., compound formulation of herbal medicine), modern personalized medicine seek to incorporate

25 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage: www.igi-global.com/chapter/ethics-privacy-considerations-systemsbiology/76124

Related Content

Recognition of Translation Initiation Sites in Arabidopsis Thaliana

Haitham Ashoor, Arturo M. Mora, Karim Awara, Boris R. Jankovic, Rajesh Chowdhary, John A.C. Archerand Vladimir B. Bajic (2012). *Systemic Approaches in Bioinformatics and Computational Systems Biology: Recent Advances (pp. 105-116).*

www.irma-international.org/chapter/recognition-translation-initiation-sites-arabidopsis/60830

Alzheimer's and Parkinson's Disease Novel Therapeutic Target: The Mitochondrial Pyruvate Carrier - Ligand Docking to Screen Natural Compounds Related to Classic Inhibitors

Allen K. Bourdon, Greg Villareal, George Perryand Clyde F. Phelix (2017). International Journal of Knowledge Discovery in Bioinformatics (pp. 68-82).

www.irma-international.org/article/alzheimers-and-parkinsons-disease-novel-therapeutic-target/190793

Mitochondrial Pyruvate Carrier 1 and 2 Heterodimer, In Silico, Models of Plant and Human Complexes: A Comparison of Structure and Transporter Binding Properties

Jason L. Dugan, Allen K. Bourdonand Clyde F. Phelix (2017). *International Journal of Knowledge Discovery in Bioinformatics (pp. 11-42).*

www.irma-international.org/article/mitochondrial-pyruvate-carrier-1-and-2-heterodimer-in-silico-models-of-plant-and-human-complexes/190791

Using Neural Natural Network for Image Recognition in Bioinformatics

Dina Kharicheva (2019). International Journal of Applied Research in Bioinformatics (pp. 35-41). www.irma-international.org/article/using-neural-natural-network-for-image-recognition-in-bioinformatics/237199

JFeature: A Java Package for Extracting Global Sequence Features from Proteins for Functional Classification

Xin Chenand Hangyang Xu (2013). *Bioinformatics: Concepts, Methodologies, Tools, and Applications (pp. 1174-1183).*

www.irma-international.org/chapter/jfeature-java-package-extracting-global/76113